# Leveraging HIV care infrastructure for implementation of context-adapted liver cancer comprehensive control strategies in Uganda: The LC3 Study

> **NIH NIH U01** · JOHNS HOPKINS UNIVERSITY · 2024 · $632,241

## Abstract

Project Summary:
For >18 years, Makerere and Johns Hopkins universities have partnered in Uganda to characterize the
epidemiology of hepatitis B (HBV) and HIV co-infection, define the subsequent sequelae including hepatocellular
carcinoma (HCC) and advance clinical management. Through an NCI-supported U54 program, we conducted
one of the largest and well-characterized studies of HCC in Africa, recruiting from both central urban and northern
rural regions of Uganda. Moreover, we have performed mixed-methods research to identify knowledge and
clinical barriers to implementation of HBV screening and diagnosis within HIV care settings. Recently, our
collaborative team successfully completed a demonstration project focused on integrating HBV diagnostic and
treatment services into HIV care in the West Nile region and also launched an implementation assessment of
antenatal care screening for and delivery of HepB birth dose vaccination at multiple sites across Uganda.
Importantly, the burden and lethality of HCC can be successfully ameliorated with implementation of evidence-
based and contextually appropriate prevention, screening, diagnostic and treatment interventions. However,
these measures have not been comprehensively implemented into routine care settings in Uganda or other high
HCC burden regions of sub-Saharan Africa. Leveraging this long-standing work in Uganda, our proposed bundle
of interventions, the Liver Cancer Comprehensive Control (LC3) package, incorporates diagnostic testing and
treatment of HBV, primary prevention through vaccination of susceptible adults, and referral for liver disease
staging and active surveillance for early HCC detection among at-risk populations. We will integrate the LC3
package into existing HIV care delivery platforms among adults living with HIV in Uganda. Our overarching goal
is to demonstrate the reach, effectiveness, and maintenance of delivering LC3 services within HIV care settings.
Successful implementation of LC3 in Uganda will serve as a model for integrating complex cancer control
intervention packages into existing HIV care delivery systems across similar countries in sub-Saharan Africa.

## Key facts

- **NIH application ID:** 11001696
- **Project number:** 1U01CA275117-01A1
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** Stefan David Baral
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $632,241
- **Award type:** 1
- **Project period:** 2024-09-03 → 2029-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11001696

## Citation

> US National Institutes of Health, RePORTER application 11001696, Leveraging HIV care infrastructure for implementation of context-adapted liver cancer comprehensive control strategies in Uganda: The LC3 Study (1U01CA275117-01A1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/11001696. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*